{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:08:45Z","timestamp":1778551725616,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"am","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08397"],"award-info":[{"award-number":["22K08397"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jdermsci.2025.05.007","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T15:58:15Z","timestamp":1748620695000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eribulin inhibits tumor growth of two novel patient-derived xenograft models of Merkel cell carcinoma"],"prefix":"10.1016","volume":"119","author":[{"given":"Kodai","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruki","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ririko","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Ujiie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2025.05.007_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/archderm.1972.01620040075020","article-title":"Trabecular carcinoma of the skin","volume":"105","author":"Toker","year":"1972","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib2","first-page":"2157","article-title":"Merkel cell carcinoma of the head and neck: pathogenesis, current and emerging treatment options","volume":"8","author":"Saini","year":"2015","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2017.10.028","article-title":"Merkel cell carcinoma: current US incidence and projected increases based on changing demographics","volume":"78","author":"Paulson","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib4","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41388-017-0073-3","article-title":"Are there multiple cells of origin of Merkel cell carcinoma?","volume":"37","author":"Sunshine","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1413793","article-title":"Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models","volume":"14","author":"Pedersen","year":"2024","journal-title":"Front Oncol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41571-018-0103-2","article-title":"The biology and treatment of Merkel cell carcinoma: current understanding and research priorities","volume":"15","author":"Harms","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.coviro.2016.07.011","article-title":"Merkel cell polyomavirus infection and Merkel cell carcinoma","volume":"20","author":"Liu","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib8","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.3390\/cancers13153737","article-title":"Targeting RB1 loss in cancers","volume":"13","author":"Linn","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.trecan.2019.03.005","article-title":"Cell cycle and beyond: exploiting new rb1 controlled mechanisms for cancer therapy","volume":"5","author":"Knudsen","year":"2019","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.jdermsci.2025.05.007_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/cas.14286","article-title":"Abemaciclib, a CDK4\/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas","volume":"111","author":"Tanaka","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bjd.13870","article-title":"Merkel cell carcinoma and Merkel cell polyomavirus: a systematic review and meta-analysis","volume":"173","author":"Santos-Juanes","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jid.2016.10.028","article-title":"Polyomavirus-negative merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection","volume":"137","author":"Moshiri","year":"2017","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib13","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1245\/s10434-016-5266-4","article-title":"Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system","volume":"23","author":"Harms","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib14","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Merkel cell carcinoma. 2023. \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mcc.pdf\u3009."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib15","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2217\/fon-2017-0072","article-title":"Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma","volume":"13","author":"Nghiem","year":"2017","journal-title":"Future Oncol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11912-021-01120-z","article-title":"Immunotherapy for non-melanoma skin cancer","volume":"23","author":"Shalhout","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jaad.2021.04.024","article-title":"Clinical impact of immunotherapy in Merkel cell carcinoma patients: a systematic review and meta-analysis","volume":"87","author":"Garza-Davila","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib18","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Schoffski","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64651-y","article-title":"Eribulin induces micronuclei and enhances the nuclear localization of cGAS in triple-negative breast cancer cells","volume":"14","author":"Yamada","year":"2024","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.jdermsci.2025.05.007_bib20","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1111\/cas.13708","article-title":"Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data","volume":"109","author":"Kawamura","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/s12935-024-03608-7","article-title":"Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer","volume":"24","author":"Feng","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib22","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1158\/1078-0432.CCR-20-4315","article-title":"Molecular biomarkers of response to eribulin in patients with leiomyosarcoma","volume":"27","author":"Wozniak","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib23","doi-asserted-by":"crossref","first-page":"8650","DOI":"10.1038\/s41598-023-35811-3","article-title":"Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft","volume":"13","author":"Hsu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib24","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1038\/s41388-020-01404-x","article-title":"Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies","volume":"39","author":"Maeda","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","article-title":"A molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","volume":"1","author":"Bertotti","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib26","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/cells8050418","article-title":"Systematic review of patient-derived xenograft models for preclinical studies of anti-cancer drugs in solid tumors","volume":"8","author":"Koga","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib28","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1111\/cas.16335","article-title":"Anti-tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models","volume":"115","author":"Tsumura","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ijc.2910550519","article-title":"Characterization of cell lines established from Merkel-cell (\u201csmall-cell\u201d) carcinoma of the skin","volume":"55","author":"Leonard","year":"1993","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib30","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.1128\/JVI.02400-09","article-title":"Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens","volume":"84","author":"Houben","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080543","article-title":"Response of Merkel cell polyomavirus-positive Merkel cell carcinoma xenografts to a survivin inhibitor","volume":"8","author":"Dresang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib32","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ijc.32280","article-title":"Characterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: integration pattern suggest that large T antigen truncating events occur before or during integration","volume":"145","author":"Schrama","year":"2019","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/jid.2014.518","article-title":"Assessment of cancer cell line representativeness using microarrays for Merkel cell carcinoma","volume":"135","author":"Daily","year":"2015","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/JCI151666","article-title":"Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma","volume":"132","author":"Lee","year":"2022","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib35","doi-asserted-by":"crossref","first-page":"e23521","DOI":"10.1016\/j.heliyon.2023.e23521","article-title":"Enhancing immunogenic responses through CDK4\/6 and HIF2\u03b1 inhibition in Merkel cell carcinoma","volume":"10","author":"Lee","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib36","doi-asserted-by":"crossref","first-page":"8867","DOI":"10.1038\/s41598-020-65637-2","article-title":"Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts","volume":"10","author":"Fang","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jdermsci.2017.02.281","article-title":"PCTAIRE1\/CDK16\/PCTK1 is overexpressed in cutaneous squamous cell carcinoma and regulates p27 stability and cell cycle","volume":"86","author":"Yanagi","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41374-018-0042-7","article-title":"Patient-derived xenograft cryopreservation and reanimation outcomes are dependent on cryoprotectant type","volume":"98","author":"Ivanics","year":"2018","journal-title":"Lab Invest"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib39","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/pin.12305","article-title":"Phosphohistone-H3 (PHH3) is prognostic relevant in Merkel cell carcinomas but Merkel cell polyomavirus is a more powerful prognostic factor than AJCC clinical stage, PHH3, Ki-67 or mitotic indices","volume":"65","author":"Iwasaki","year":"2015","journal-title":"Pathol. Int"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib40","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ijc.24510","article-title":"Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors","volume":"125","author":"Shuda","year":"2009","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180426","article-title":"Expression of Merkelcell polyomavirus (MCPyV) large T-antigen in Merkel cell carcinoma lymph node metastases predicts poor outcome","volume":"12","author":"Haymerle","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib42","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-10-3363","article-title":"Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in Merkel cell carcinoma","volume":"17","author":"Sihto","year":"2011","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib43","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1158\/1078-0432.CCR-08-0138","article-title":"Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers","volume":"14","author":"Fichtner","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1046\/j.1523-1747.2000.00937.x","article-title":"Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice","volume":"114","author":"Schlagbauer-Wadl","year":"2000","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib45","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.2147\/IJN.S298093","article-title":"Anti-cancer activity based on the high docetaxel loaded poly(2-oxazoline)s micelles","volume":"16","author":"Xu","year":"2021","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.jdermsci.2025.05.007_bib46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.18632\/oncotarget.26536","article-title":"Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo","volume":"10","author":"Watanabe","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib47","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cancers14010210","article-title":"Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2\/M Cell Cycle Phase","volume":"14","author":"Pandey","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib48","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1021\/ci200077t","article-title":"Interactions of halichondrin B and eribulin with tubulin","volume":"51","author":"Bai","year":"2011","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2218782","article-title":"Eribulin mesylate exerts antitumor effects via CD103","volume":"12","author":"Oya","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jdermsci.2025.05.007_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40425-019-0518-z","article-title":"Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts","volume":"7","author":"Capasso","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181125000994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181125000994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:13:56Z","timestamp":1778548436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181125000994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0923181125000994"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2025.05.007","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eribulin inhibits tumor growth of two novel patient-derived xenograft models of Merkel cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2025.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}